About one third of HIV-positive people studied at Albany Medical Center had an important drug-drug interaction involving one of the medications in a first antiretroviral combination that included a protease inhibitor (PI), a nonnucleoside (NNRTI), or the integrase inhibitor
Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor
The safety profile is based on pooled data from Phase IIb and Phase III clinical studies in 980 previously untreated patients, 357 previously treated patients unexposed to integrase inhibitors
and 234 patients with prior treatment failure that included an integrase inhibitor
(including integrase class resistance).
, the latest weapon in the HIV treatment armamentarium, stop HIV from incorporating its genetic information into the DNA of an infected T cell, essentially heading off HIV's master plan to hijack all future generations of cells.
S/GSK1349572, which is being developed by GlaxoSmithKline, is an other second-generation integrase inhibitor
that may be headed to phase II/III clinical trials.
The protease inhibitor Prezista and the integrase inhibitor
Isentress could be detected in all CSF samples analyzed in separate studies of people taking these, anti-retrovirals.
N155H is a key resistance mutation for the integrase inhibitors
Elvitegravir is a member of the integrase inhibitor
class of antiretroviral compounds.
ViiV Healthcare's first investigational once-daily single-tablet regimen, combining the integrase inhibitor
dolutegravir and nucleoside analogues abacavir/lamivudine
Standard HIV-drug therapy contains three active components: a backbone of two NRTIs, plus either a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), Protease Inhibitor (PI) or Integrase Inhibitor
It is a human immunodeficiency virus type 1 (HIV-1) integrase inhibitor
SAN FRANCISCO -- For the first time, an integrase inhibitor
is included in the preferred first-line antiretroviral regimens for adolescents and adults with HIV, and another integrase inhibitor
may be starting phase II/III clinical trials.